Johnson & Johnson and Bayer’s legacy blood thinner Xarelto has had a tough year with competitors picking up steam and prescriptions leveling off. But in a hard-to-treat artery disease, Xarelto just posted a new trial in recent post-surgery patients. More: ACC:
read moreAs the COVID-19 pandemic swells, experts around the globe are working to determine which existing medicines might help patients experiencing severe illness. Malaria drug chloroquine has gotten a lot of the attention, but now a team suggests a Roche stroke drug is
read moreFirst it was the manufacturing process. Now, the novel coronavirus has forced Bluebird Bio to further delay treating patients with its gene therapy Zynteglo in Europe. On top of the COVID-19 impact, the biotech still hasn’t reached an agreement with
read moreIn an unusual display of coordinated frankness for the industry, a coalition representing generic drug makers, insurers, pharmacies and benefit managers told Vice President Mike Pence and congressional leaders that some policies in place or under consideration to fight COVID-19
read moreThe specter of global drug shortages looms large amid the coronavirus pandemic. But so far, the supply chain is holding steady and prices are going up—in the generic drug business, at least. One analyst, in fact, figures COVID-19 could turn
read moreIntercept Pharmaceuticals and its closely watched nonalcoholic steatohepatitis (NASH) candidate have hit another snag, this one courtesy of the coronavirus pandemic. The FDA has put off an advisory committee review of obeticholic acid, now the lead horse in the hotly contested NASH
read more© 1994 - 2026 B.M. Pharmaceuticals